IOVA

+ Watchlist + Portfolio

Iovance Biotherapeutics, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $7.99
52-Week Range: $1.76 – $9.36
Market Cap: $4.07B
P/E (TTM): —
EPS (TTM): -0.69
Dividend Yield: —

Advanced Metrics

Price/Book: 5.53
PEG Ratio: —
Return on Equity: -40.36%
Return on Assets: -20.31%
Gross Margin: 48.40%
Operating Margin: -52.26%
Profit Margin: -89.09%
Current Ratio: 4.34
Debt/Equity: 0.06
Total Debt: $46.00M
Free Cash Flow: $-187.79M
Revenue Growth: 65.70%
Earnings Growth: —
Enterprise Value: $3.37B

IOVA Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$1.19M	$164.07M	$263.50M
Cost of Revenue	$0.00	$1.03M	$93.25M	$173.18M
Gross Profit	$0.00	$156.00K	$70.82M	$90.32M
Research & Development	$294.78M	$333.19M	$276.23M	$300.27M
Selling, General & Admin	$104.10M	$106.10M	$152.27M	$152.32M
Operating Expenses	$398.88M	$460.71M	$466.10M	$488.53M
Operating Income	-$398.88M	-$460.56M	-$395.28M	-$398.21M
EBITDA	-$377.74M	-$427.43M	-$347.21M	-$350.89M
Pretax Income	-$395.89M	-$447.52M	-$375.00M	-$393.05M
Income Tax	$0.00	-$3.48M	-$2.83M	-$2.07M
Net Income	-$395.89M	-$444.04M	-$372.18M	-$390.98M
Diluted EPS	-2.49	-1.89	-1.28	-1.09
Diluted Shares	159.26M	235.13M	289.88M	357.35M

IOVA Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$231.73M	$114.89M	$115.69M	$163.08M
Receivables	$0.00	$151.00K	$69.34M	$82.45M
Inventory	$0.00	$10.37M	$51.52M	$51.68M
Current Assets	$479.12M	$307.85M	$457.02M	$442.69M
Total Assets	$663.98M	$780.35M	$910.43M	$913.17M
Current Liabilities	$91.48M	$110.31M	$122.34M	$138.36M
Long-Term Debt	$1.00M	$1.00M	$1.00M	—
Total Debt	$85.45M	$75.86M	$58.26M	$49.44M
Total Liabilities	$164.34M	$195.74M	$200.02M	$214.59M
Retained Earnings	-$1.57B	-$2.01B	-$2.38B	-$2.78B
Shareholders' Equity	$499.64M	$584.61M	$710.40M	$698.58M
Working Capital	$387.63M	$197.54M	$334.68M	$304.33M

IOVA Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$292.76M	-$361.82M	-$352.98M	-$302.41M
Capital Expenditure	-$20.43M	-$22.29M	-$11.07M	-$33.84M
Free Cash Flow	-$313.18M	-$384.11M	-$364.05M	-$336.24M
Depreciation & Amortisation	$21.14M	$33.13M	$48.07M	$47.32M
Stock-Based Compensation	$84.02M	$62.63M	$109.63M	$61.58M
Investing Cash Flow	$256.45M	-$155.24M	-$96.41M	$47.50M
Financing Cash Flow	$190.15M	$462.96M	$390.66M	$300.77M
Net Change in Cash	$153.85M	-$54.10M	-$58.72M	$45.86M

IOVA Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$49.32M	$59.95M	$67.45M	$86.77M	$71.43M
Cost of Revenue	$42.72M	$56.66M	$38.48M	$43.11M	$42.50M
Gross Profit	$6.61M	$3.29M	$28.98M	$43.66M	$28.93M
Research & Development	$75.97M	$79.36M	$75.17M	$71.20M	$62.49M
Selling, General & Admin	$43.80M	$37.70M	$34.55M	$36.40M	$38.95M
Operating Expenses	$127.83M	$117.06M	$118.74M	$117.12M	$109.97M
Operating Income	-$121.22M	-$113.77M	-$89.76M	-$73.46M	-$81.04M
EBITDA	-$110.29M	-$101.71M	-$78.08M	-$60.82M	-$70.63M
Pretax Income	-$118.00M	-$109.67M	-$93.66M	-$71.72M	-$79.71M
Income Tax	-$1.84M	$1.99M	-$2.40M	$184.00K	-$665.00K
Net Income	-$116.16M	-$111.66M	-$91.25M	-$71.90M	-$79.05M
Diluted EPS	-0.36	-0.33	-0.25	-0.18	-0.19
Diluted Shares	322.87M	334.51M	364.04M	406.97M	418.51M

IOVA Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$171.67M	$132.47M	$158.13M	$163.08M	$196.51M
Receivables	$70.94M	$59.94M	$66.76M	$82.45M	$81.76M
Inventory	$65.55M	$49.83M	$51.71M	$51.68M	$58.38M
Current Assets	$512.65M	$422.50M	$429.09M	$442.69M	$466.50M
Total Assets	$966.74M	$907.44M	$904.95M	$913.17M	$925.66M
Current Liabilities	$122.69M	$129.16M	$125.78M	$138.36M	$129.42M
Total Debt	$53.72M	$53.17M	$52.49M	$49.44M	$47.78M
Total Liabilities	$198.88M	$208.95M	$202.66M	$214.59M	$203.91M
Retained Earnings	-$2.50B	-$2.61B	-$2.70B	-$2.78B	-$2.85B
Shareholders' Equity	$767.87M	$698.49M	$702.29M	$698.58M	$721.75M
Working Capital	$389.96M	$293.35M	$303.31M	$304.33M	$337.08M

IOVA Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$103.69M	-$67.45M	-$78.70M	-$52.56M	-$72.07M
Capital Expenditure	-$6.21M	-$7.46M	-$10.84M	-$9.32M	-$6.61M
Free Cash Flow	-$109.91M	-$74.91M	-$89.55M	-$61.88M	-$78.68M
Depreciation & Amortisation	$10.94M	$12.07M	$11.68M	$12.64M	$10.41M
Stock-Based Compensation	$22.91M	$14.94M	$11.90M	$11.82M	$11.27M
Investing Cash Flow	$15.87M	$13.84M	$17.01M	$775.00K	$11.39M
Financing Cash Flow	$143.31M	$13.23M	$88.06M	$56.17M	$94.33M
Net Change in Cash	$55.49M	-$40.38M	$26.37M	$4.38M	$33.66M

Market Snapshot

About

Iovance Biotherapeutics is a clinical-stage biotechnology company developing tumor-infiltrating lymphocyte (TIL) therapies for cancer treatment. The company's approach involves extracting immune cells from a patient's tumor, expanding them in the lab, and infusing them back to fight cancer. Iovance's lead programs target solid tumors including melanoma, cervical cancer, and head and neck cancers. The company's TIL therapy represents a personalized immunotherapy approach distinct from CAR-T and other cell therapies.